Thursday, June 29, 2023
Astellas Pharma and Mitsui Fudosan plans to establish a groundbreaking open innovation hub named "TME iLab" (TME imaging and interactive research for innovation). This innovative hub is set to launch in October 2023 at MITSUI LINK-Lab KASHIWA-NO-HA 1.
The partnership aims to leverage the advantages of the Kashiwa-no-ha area, which is renowned for its proximity to prominent Japanese medical facilities and academic institutions. By harnessing the expertise and resources available in this region, including the National Cancer Centre Japan, the two companies seek to tackle the complex issue of the tumour microenvironment in refractory cancer.
Astellas aims to accelerate the research and development of anticancer drugs and foster innovation by leveraging its drug discovery capabilities in collaboration with partners such as academia and venture companies. By combining Astellas' expertise with the knowledge and resources of these partners, it aims to expedite the discovery and creation of innovative drugs to combat cancer.
Bringing together cutting-edge science from multiple fields and integrating it into research and development is indeed crucial for the discovery of innovative drugs, including anticancer drugs. Using cutting-edge facilities and technologies, researchers can advance the understanding of tumour microenvironment, select biomarkers for effective therapies, and identify candidate target molecules for new therapeutic targets.
